(Q48686096)

14 February 2018

title

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. (English)

1 reference

14 February 2018

1 reference

Marta Mellai

1

1 reference

14 February 2018

Oriana Monzeglio

2

1 reference

14 February 2018

Angela Piazzi

3

1 reference

14 February 2018

Valentina Caldera

4

1 reference

14 February 2018

Laura Annovazzi

5

1 reference

14 February 2018

Paola Cassoni

6

1 reference

14 February 2018

Guido Valente

7

1 reference

14 February 2018

Susanna Cordera

8

1 reference

14 February 2018

Cristina Mocellini

9

1 reference

14 February 2018

Davide Schiffer

10

1 reference

14 February 2018

publication date

1 May 2012

1 reference

14 February 2018

Journal of Neuro-Oncology

published in

1 reference

14 February 2018

volume

107

1 reference

14 February 2018

issue

3

1 reference

14 February 2018

page(s)

617-631

1 reference

14 February 2018

https://scigraph.springernature.com/pub.10.1007/s11060-011-0787-y

exact match

0 references

cites work

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6 -methylguanine DNA methyltransferase gene promoter methylation in high-grade gliomas: a review of current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Aberrant hypermethylation of p14ARF and O6-methylguanine-DNA methyltransferase genes in astrocytoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6-methylguanine-DNA methyltransferase methylation and TP53 mutation in malignant astrocytomas and their relationships with clinical course

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Quantitative analysis of O6-methylguanine DNA methyltransferase (MGMT) promoter methylation in patients with low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Methylation status of MGMT gene promoter in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Antigenic and Genotypic Similarity between Primary Glioblastomas and Their Derived Neurospheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Genetic pathways to primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Molecular diagnostics of gliomas: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Molecular genetic markers as predictors of response to chemotherapy in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Two types of chromosome 1p losses with opposite significance in gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Mutant metabolic enzymes are at the origin of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

A microarray-based DNA methylation study of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Molecular subclassification of diffuse gliomas: seeing order in the chaos

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

MGMT promoter methylation status in anaplastic meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-011-0787-Y

Immunohistochemical assessment of MGMT expression and p53 mutation in glioblastoma multiforme.

21 January 2018

1 reference

12 December 2020

Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.

1 reference

12 December 2020

Promoter Hypermethylation of the DNA Repair Gene O6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

1 reference

12 December 2020

A polymerase chain reaction-based assay for the rapid detection of gene amplification in human tumors

1 reference

12 December 2020

Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.

1 reference

12 December 2020

Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas

1 reference

12 December 2020

Recurrent PNET with MGMT methylation responds to temozolomide

1 reference

12 December 2020

Chromosome 1p loss evaluation in anaplastic oligodendrogliomas

1 reference

12 December 2020

Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas

1 reference

12 December 2020

MGMT promoter hypermethylation in a series of 104 glioblastomas

1 reference

12 December 2020

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia

1 reference

12 December 2020

10.1007/S11060-011-0787-Y

Identifiers

DOI

1 reference

14 February 2018

1 reference

14 February 2018